Drugs / Porcine PERT
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT04375878 Comparator | Jul 2020 → Apr 2021 | cystic fibrosis, exocrine pancreatic insufficiency | Entero Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT03051490 Comparator | Apr 2017 → Feb 2018 | cystic fibrosis, exocrine pancreatic insufficiency | Anthera Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Porcine PERT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04375878 ↗ |
| Action | Restore | “pancreatic enzyme replacement” NCT03051490 ↗ |
| Modality | Protein / enzyme biologic | “pig-derived, pancreatic enzyme replacement” NCT03051490 ↗ |
| Route | Oral | “administered orally” NCT03051490 ↗ |